Medpace (MEDP) Stock Forecast, Price Target & Predictions
MEDP Stock Forecast
Medpace stock forecast is as follows: an average price target of $399.20 (represents a 29.22% upside from MEDP’s last price of $308.93) and a rating consensus of 'Hold', based on 11 wall street analysts offering a 1-year stock forecast.
MEDP Price Target
The average price target for Medpace (MEDP) is $399.20 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $452.00 to $345.00. This represents a potential 29.22% upside from MEDP's last price of $308.93.
MEDP Analyst Ratings
According to 11 Wall Street analysts, Medpace's rating consensus is 'Hold'. The analyst rating breakdown for MEDP stock is 0 'Strong Buy' (0.00%), 5 'Buy' (45.45%), 6 'Hold' (54.55%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Medpace Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 23, 2024 | Eric Coldwell | Robert W. Baird | $349.00 | $326.54 | 6.88% | 12.97% |
| Sep 25, 2024 | David Windley | Jefferies | $345.00 | $355.82 | -3.04% | 11.68% |
| Aug 01, 2024 | Jailendra Singh | Truist Financial | $415.00 | $382.52 | 8.49% | 34.33% |
| Jul 08, 2024 | Eric Coldwell | Robert W. Baird | $469.00 | $404.13 | 16.05% | 51.81% |
| Jun 13, 2024 | Eric Coldwell | Robert W. Baird | $456.00 | $403.74 | 12.94% | 47.61% |
| May 28, 2024 | Ann Hynes | Mizuho Securities | $435.00 | $390.55 | 11.38% | 40.81% |
| Apr 23, 2024 | David Windley | Jefferies | $450.00 | $376.26 | 19.60% | 45.66% |
| Feb 15, 2024 | John Sourbeer | UBS | $452.00 | $394.34 | 14.62% | 46.31% |
The latest Medpace stock forecast, released on Oct 23, 2024 by Eric Coldwell from Robert W. Baird, set a price target of $349.00, which represents a 6.88% increase from the stock price at the time of the forecast ($326.54), and a 12.97% increase from MEDP last price ($308.93).
Medpace Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 8 |
| Avg Price Target | $349.00 | $347.00 | $421.38 |
| Last Closing Price | $308.93 | $308.93 | $308.93 |
| Upside/Downside | 12.97% | 12.32% | 36.40% |
In the current month, the average price target of Medpace stock is $349.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 12.97% increase as opposed to Medpace's last price of $308.93. This month's average price target is up 0.58% compared to last quarter, and down -17.18% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 22, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 27, 2024 | UBS | Buy | Neutral | Downgrade |
| Sep 25, 2024 | Jefferies | Buy | Hold | Downgrade |
| May 29, 2024 | Cowen & Co. | - | Buy | Initialise |
| Apr 23, 2024 | Jefferies | - | Buy | Upgrade |
| Feb 15, 2024 | UBS | Neutral | Buy | Upgrade |
| Oct 24, 2023 | Barclays | - | Outperform | Upgrade |
| May 08, 2023 | Guggenheim | Neutral | Buy | Upgrade |
| Oct 27, 2022 | RBC Capital | - | Sector Perform | Downgrade |
| Oct 27, 2022 | Goldman Sachs | - | Sector Weight | Downgrade |
Medpace's last stock rating was published by Cowen & Co. on Oct 22, 2024. The company gave MEDP a "Buy" rating, the same as its previous rate.
Medpace Financial Forecast
Medpace Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $460.87M | $434.07M | $394.10M | $383.74M | $351.21M | $330.95M | $308.55M | $295.57M | $278.29M | $259.96M | $259.68M | $230.37M | $205.00M | $230.88M | $229.89M | $216.24M |
| Avg Forecast | $661.28M | $642.39M | $620.12M | $597.97M | $574.74M | $560.86M | $547.96M | $537.55M | $534.94M | $540.99M | $528.40M | $512.39M | $498.72M | $475.79M | $433.75M | $401.80M | $386.01M | $357.17M | $344.01M | $327.09M | $309.04M | $291.56M | $272.10M | $265.29M | $245.96M | $218.58M | $182.50M | $226.32M | $222.37M | $217.15M |
| High Forecast | $669.69M | $650.55M | $628.01M | $605.58M | $582.05M | $567.99M | $554.93M | $540.13M | $536.84M | $541.71M | $528.41M | $512.39M | $505.06M | $476.71M | $439.27M | $406.91M | $390.92M | $357.17M | $344.01M | $327.09M | $309.04M | $291.56M | $272.10M | $265.29M | $245.96M | $218.58M | $182.50M | $226.32M | $222.37M | $217.15M |
| Low Forecast | $653.94M | $635.25M | $613.24M | $591.33M | $568.35M | $554.63M | $541.88M | $534.98M | $531.88M | $540.28M | $528.40M | $512.39M | $493.18M | $474.56M | $428.93M | $397.34M | $381.73M | $357.17M | $344.01M | $327.09M | $309.04M | $291.56M | $272.10M | $265.29M | $245.96M | $218.58M | $182.50M | $226.32M | $222.37M | $217.15M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 1 | 1 | 1 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 16 | 8 | 11 | 7 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.08% | 1.02% | 1.07% | 1.02% | 1.01% | 1.00% | 1.01% | 1.02% | 0.98% | 1.06% | 1.05% | 1.12% | 1.02% | 1.03% | 1.00% |
Medpace's average Quarter revenue forecast for Sep 23 based on 5 analysts is $475.79M, with a low forecast of $474.56M, and a high forecast of $476.71M. MEDP's average Quarter revenue forecast represents a 3.24% increase compared to the company's last Quarter revenue of $460.87M (Jun 23).
Medpace EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 1 | 1 | 1 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 16 | 8 | 11 | 7 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $83.63M | $92.16M | $82.33M | $89.27M | $68.09M | $69.31M | $60.32M | $59.05M | $47.68M | $52.69M | $60.47M | $51.36M | $34.78M | $39.95M | $41.15M | $34.77M |
| Avg Forecast | $127.94M | $124.28M | $119.98M | $115.69M | $111.19M | $108.51M | $106.01M | $104.00M | $103.49M | $104.67M | $102.23M | $56.18M | $96.49M | $92.05M | $83.92M | $51.07M | $63.77M | $69.17M | $66.63M | $46.43M | $59.85M | $56.47M | $52.70M | $46.10M | $47.64M | $42.33M | $35.35M | $40.38M | $43.07M | $42.06M |
| High Forecast | $129.57M | $125.86M | $121.50M | $117.16M | $112.61M | $109.89M | $107.36M | $104.50M | $103.86M | $104.80M | $102.23M | $67.42M | $97.71M | $92.23M | $84.99M | $61.29M | $76.52M | $69.17M | $66.63M | $55.72M | $59.85M | $56.47M | $52.70M | $55.31M | $47.64M | $42.33M | $35.35M | $48.46M | $43.07M | $42.06M |
| Low Forecast | $126.52M | $122.90M | $118.64M | $114.40M | $109.96M | $107.30M | $104.84M | $103.50M | $102.90M | $104.53M | $102.23M | $44.95M | $95.41M | $91.81M | $82.99M | $40.86M | $51.01M | $69.17M | $66.63M | $37.15M | $59.85M | $56.47M | $52.70M | $36.88M | $47.64M | $42.33M | $35.35M | $32.31M | $43.07M | $42.06M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 1.80% | 1.29% | 1.29% | 1.02% | 1.49% | 1.01% | 1.05% | 0.90% | 1.14% | 1.27% | 1.21% | 0.98% | 0.99% | 0.96% | 0.83% |
5 analysts predict MEDP's average Quarter EBITDA for Sep 23 to be $92.05M, with a high of $92.23M and a low of $91.81M. This is 10.07% upper than Medpace's previous annual EBITDA (Jun 23) of $83.63M.
Medpace Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 1 | 1 | 1 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 16 | 8 | 11 | 7 | 11 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $61.07M | $72.89M | $68.67M | $66.03M | $49.36M | $61.31M | $50.03M | $48.57M | $39.93M | $43.31M | $50.87M | $41.46M | $24.10M | $28.95M | $29.81M | $23.98M |
| Avg Forecast | $122.15M | $116.28M | $110.86M | $112.16M | $104.20M | $100.81M | $96.75M | $95.94M | $94.38M | $88.90M | $81.46M | $48.87M | $71.26M | $65.66M | $61.43M | $44.43M | $51.96M | $47.31M | $42.10M | $40.39M | $40.11M | $34.65M | $31.76M | $37.24M | $39.79M | $34.44M | $12.72M | $28.57M | $24.22M | $22.89M |
| High Forecast | $124.17M | $118.20M | $112.69M | $114.01M | $105.92M | $102.48M | $98.35M | $97.53M | $96.92M | $89.30M | $81.47M | $58.64M | $72.43M | $66.94M | $62.45M | $53.31M | $62.35M | $47.31M | $42.10M | $48.46M | $40.11M | $34.65M | $32.10M | $44.69M | $39.79M | $34.44M | $12.72M | $34.28M | $24.22M | $22.89M |
| Low Forecast | $120.38M | $114.60M | $109.26M | $110.54M | $102.70M | $99.36M | $95.35M | $94.56M | $91.20M | $88.51M | $81.45M | $39.10M | $70.23M | $64.06M | $60.54M | $35.54M | $41.56M | $47.31M | $42.10M | $32.31M | $40.11M | $34.65M | $31.41M | $29.79M | $39.79M | $34.44M | $12.72M | $22.85M | $24.22M | $22.89M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.99% | 1.64% | 1.32% | 1.40% | 1.17% | 1.52% | 1.25% | 1.40% | 1.26% | 1.16% | 1.28% | 1.20% | 1.89% | 1.01% | 1.23% | 1.05% |
Medpace's average Quarter net income forecast for Sep 23 is $65.66M, with a range of $64.06M to $66.94M. MEDP's average Quarter net income forecast represents a 7.52% increase compared to the company's last Quarter net income of $61.07M (Jun 23).
Medpace SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 1 | 1 | 1 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 16 | 8 | 11 | 7 | 11 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $39.40M | $38.03M | $33.40M | $35.42M | $33.22M | $29.37M | $27.66M | $28.05M | $26.97M | $25.74M | $22.38M | $22.80M | $21.86M | $25.12M | $21.26M | $29.12M |
| Avg Forecast | $63.57M | $61.75M | $59.61M | $57.48M | $55.25M | $53.91M | $52.67M | $51.67M | $51.42M | $52.00M | $50.79M | $23.41M | $47.94M | $45.74M | $41.69M | $21.28M | $28.73M | $34.33M | $33.07M | $19.34M | $29.71M | $28.03M | $26.16M | $22.13M | $23.64M | $21.01M | $17.54M | $29.18M | $21.38M | $20.87M |
| High Forecast | $64.37M | $62.53M | $60.37M | $58.21M | $55.95M | $54.60M | $53.34M | $51.92M | $51.60M | $52.07M | $50.79M | $28.09M | $48.55M | $45.82M | $42.22M | $25.53M | $34.47M | $34.33M | $33.07M | $23.21M | $29.71M | $28.03M | $26.16M | $26.56M | $23.64M | $21.01M | $17.54M | $35.02M | $21.38M | $20.87M |
| Low Forecast | $62.86M | $61.06M | $58.95M | $56.84M | $54.63M | $53.31M | $52.09M | $51.42M | $51.13M | $51.93M | $50.79M | $18.73M | $47.41M | $45.62M | $41.23M | $17.02M | $22.98M | $34.33M | $33.07M | $15.48M | $29.71M | $28.03M | $26.16M | $17.71M | $23.64M | $21.01M | $17.54M | $23.34M | $21.38M | $20.87M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.95% | 1.79% | 1.16% | 1.03% | 1.00% | 1.52% | 0.93% | 1.00% | 1.03% | 1.16% | 0.95% | 1.08% | 1.25% | 0.86% | 0.99% | 1.40% |
Medpace's average Quarter SG&A projection for Sep 23 is $45.74M, based on 5 Wall Street analysts, with a range of $45.62M to $45.82M. The forecast indicates a 16.07% rise compared to MEDP last annual SG&A of $39.40M (Jun 23).
Medpace EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 1 | 1 | 1 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 16 | 8 | 11 | 7 | 11 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.00 | $2.35 | $2.20 | $2.13 | $1.52 | $1.75 | $1.39 | $1.35 | $1.11 | $1.21 | $1.43 | $1.16 | $0.68 | $0.80 | $0.82 | $0.67 |
| Avg Forecast | $3.81 | $3.62 | $3.45 | $3.50 | $3.25 | $3.14 | $3.02 | $2.99 | $2.94 | $2.77 | $2.54 | $2.47 | $2.22 | $2.05 | $1.91 | $1.82 | $1.79 | $1.47 | $1.31 | $1.26 | $1.25 | $1.08 | $0.99 | $1.00 | $1.24 | $1.07 | $0.40 | $0.74 | $0.76 | $0.71 |
| High Forecast | $3.87 | $3.68 | $3.51 | $3.55 | $3.30 | $3.19 | $3.06 | $3.04 | $3.02 | $2.78 | $2.54 | $2.47 | $2.26 | $2.09 | $1.95 | $1.85 | $1.87 | $1.47 | $1.31 | $1.26 | $1.25 | $1.08 | $1.00 | $1.00 | $1.24 | $1.07 | $0.40 | $0.74 | $0.76 | $0.71 |
| Low Forecast | $3.75 | $3.57 | $3.41 | $3.44 | $3.20 | $3.10 | $2.97 | $2.95 | $2.84 | $2.76 | $2.54 | $2.47 | $2.19 | $2.00 | $1.89 | $1.79 | $1.70 | $1.47 | $1.31 | $1.26 | $1.25 | $1.08 | $0.98 | $1.00 | $1.24 | $1.07 | $0.40 | $0.74 | $0.76 | $0.71 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 1.29% | 1.23% | 1.44% | 1.16% | 1.39% | 1.11% | 1.25% | 1.12% | 1.20% | 1.15% | 1.08% | 1.72% | 1.08% | 1.09% | 0.94% |
According to 5 Wall Street analysts, Medpace's projected average Quarter EPS for Sep 23 is $2.05, with a low estimate of $2.00 and a high estimate of $2.09. This represents a 2.31% increase compared to MEDP previous annual EPS of $2.00 (Jun 23).
Medpace Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ICLR | ICON Public Limited Company | $187.22 | $309.60 | 65.37% | Buy |
| CRL | Charles River Laboratories | $187.50 | $303.60 | 61.92% | Buy |
| IQV | IQVIA | $191.04 | $266.65 | 39.58% | Buy |
| MEDP | Medpace | $308.93 | $399.20 | 29.22% | Hold |
| QGEN | Qiagen | $40.99 | $51.89 | 26.59% | Buy |
| LH | Laboratory Corporation of America | $238.64 | $281.25 | 17.86% | Buy |
| RVTY | Revvity | $109.47 | $126.88 | 15.90% | Buy |
| NEOG | Neogen | $15.20 | $17.50 | 15.13% | Buy |
| MTD | Mettler-Toledo | $1.17K | $1.34K | 14.46% | Hold |
| IDXX | IDEXX Laboratories | $419.83 | $479.75 | 14.27% | Buy |
| TWST | Twist Bioscience | $41.43 | $42.40 | 2.34% | Buy |
| WAT | Waters | $355.47 | $356.80 | 0.37% | Buy |